Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05060718
Other study ID # HONEST-PREPS
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 20, 2020
Est. completion date January 12, 2023

Study information

Verified date December 2022
Source UMC Utrecht
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Hospital Acquired and Ventilator Associated Pneumonia (HAP/VAP) pose a significant burden to patients admitted to the Intensive Care Unit (ICU). Reported incidence ranges from 10-16% in all ICU patients (including HAP and VAP) and around 20-30% in ventilated patients (VAP). Patients with HAP/VAP have a high mortality rate. The estimated attributable mortality of VAP is 6-13%. Randomized Controlled Trials (RCTs) are the gold standard for evaluating medical interventions, but are difficult to perform in this population. Several preventive and therapeutic treatment options are being developed that will require evaluation in phase-III trials. These trials are challenging due to the relatively low incidence of the outcome (e.g. HAP/VAP) or of the domain under study (e.g. specific antibiotic resistant infections) and the requirement of informed consent in critically ill patients. There is a need for a well-organized and well-trained international RCT network that enables efficient execution of a series of RCTs in this population. The aim of the current study is to set up an infrastructure to prospectively enroll patients at risk of HAP/VAP in ICUs in several European countries. Site personnel will be trained to obtain a GCP (Good Clinical Practice) certification (if not already done), to timely identify and enroll patients at risk of HAP/VAP, to timely identify occurrence of HAP/VAP, collect informed consent forms, collect source data, enter data into a clinical database, and use a dedicated system to reply to queries. Site sample collection, processing, identifying the causative organism, and antibiotic susceptibility testing will be validated and adapted if required where possible. Where site infrastructure and regulations allow, the possibility of automated data collection of included participants will be explored to ensure sustainability of the future platform. Furthermore, collected data will be used to inform future diagnostic, preventive and therapeutic trials. E.g. they may support assumptions in sample size calculations and expected number of enrolled participants, they may help in prioritizing interventions, or they may be used in simulations of adaptive trials to optimize decision rules.


Recruitment information / eligibility

Status Completed
Enrollment 2165
Est. completion date January 12, 2023
Est. primary completion date May 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age >= 18 years - At risk of acquiring bacterial HAP or VAP during ICU stay, defined as meeting all of the following criteria: - expected or documented hospital length of stay of more than 48 hours - admitted to the ICU Exclusion Criteria: - Death is deemed to be imminent or inevitable during this hospital admission AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment

Study Design


Locations

Country Name City State
Albania University Trauma Hospital Tirana
Croatia Clinical Hospital Center Rijeka Rijeka
Croatia General Hospital Dr Josip Bencevic Slavonski Brod Slavonski Brod
Czechia Regional Hospital Kolin Kolín
Czechia General University Hospital Prague Praha
Czechia University Hospital Kralovske Vinohrady Praha
Czechia University Hospital Motol Praha
France CHU de Limoges Limoges
Latvia Liepaja Regional Hospital Liepaja
Latvia Paul Stradins Clinical University Hospital Riga
Romania Central Military Emergency University Hospital "Dr. Carol Davila " Bucharest
Romania Elias University Emergency Hospital Bucharest
Serbia Clinical Center of Serbia Belgrade
Serbia Clinical Center Kragujevac Kragujevac
Serbia Clinical Center of Vojvodina Novi Sad
Serbia Institute for Pulmonary Diseases of Vojvodina Novi Sad

Sponsors (3)

Lead Sponsor Collaborator
UMC Utrecht Universiteit Antwerpen, University Hospital, Geneva

Countries where clinical trial is conducted

Albania,  Croatia,  Czechia,  France,  Latvia,  Romania,  Serbia, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine the quality and efficiency of a research platform for HAP/VAP in ICUs by measuring the timeliness of enrolling eligible patients. Assess the proportion of screened, eligible patients at risk of developing HAP or VAP by being enrolled within 48 hours of ICU admission. Through study completion, an average of 2 years
Primary To determine the quality and efficiency of a research platform for HAP/VAP in ICUs by capturing bacterial HAP/VAP episodes. Analyse the proportion of enrolled patients who develop HAP/VAP during the initial ICU admission and who are registered in the eCRF (electronic Case Report Form) within 24 hours after onset. Onset is defined as the time of X-ray showing an infiltrate confirming HAP/VAP for patients meeting HAP/VAP FDA criteria. Through study completion, an average of 2 years
Secondary To determine the incidence of HAP/VAP at the ICU. -Incidence of HAP and VAP per 1,000 patient-days From the date of enrolment through to the date of ICU discharge, an average of 11 days
Secondary To determine the implementation of infection prevention and control measures in routine ICU care for prevention of HAP/VAP. -Implementation of ICU-level HAP/VAP infection prevention measures From the date of enrolment through to the date of ICU discharge, an average of 11 days
Secondary To determine microbiological etiology of HAP/VAP at the ICU (1). -Microbiological cure between 7 and 10 days after HAP/VAP onset (%). (Proportion of patients with positive HAP/VAP diagnosis with the resolution of the symptoms between day 7-10 after the onset) Between days 7 and 10 after HAP/VAP onset
Secondary To determine microbiological etiology of HAP/VAP at the ICU (2). -Distribution of bacterial pathogens (%). (Proportion of identified bacterial pathogens associated with HAP/VAP episode). +/- 48 hours of HAP/VAP onset
Secondary To determine microbiological etiology of HAP/VAP at the ICU (3) -Resistance profiles of bacterial pathogens (% resistant) (proportion of resistant bacterial pathogen associated with HAP/VAP episode). +/- 48 hours of HAP/VAP onset
Secondary To determine management of HAP/VAP at the ICU (1) -IMV (Invasive Mechanical Ventilation)-free-days up to 28 days after VAP onset (days). From the date of enrolment through to the date of ICU discharge, on average of 6 days
Secondary To determine management of HAP/VAP at the ICU (2) -Antibiotic consumption before and after HAP/VAP (type of antibiotic administered per patient). From the date of enrolment through to the date of ICU discharge, on average of 11 days
Secondary To determine management of HAP/VAP at the ICU (3). -Survival up to 90 days post HAP/VAP onset rate (%) (Proportion of patient's confirmed alive vs. dead in %) 90 days after HAP/VAP onset
Secondary To determine outcome of HAP/VAP at the ICU (1). -ICU survival rate (%). (Proportion of patients discharged from ICU alive vs. patients with in-ICU death) From the date of HAP/VAP onset through to the date of ICU discharge, on average of 11 days
Secondary To determine outcome of HAP/VAP at the ICU (2). -Hospital survival rate (%). (Proportion of patients discharged from hospital alive vs. patients with in-hospital death) From the date of HAP/VAP onset through to the date of hospital discharge, on average of 12 days
Secondary To determine outcome of HAP/VAP at the ICU (3). -Length of ICU stay before and after HAP/VAP (number of days spent in ICU before and after HAP/VAP onset) From the date of enrolment through to the date of ICU discharge, on average of 11 days
Secondary To determine outcome of HAP/VAP at the ICU (4). -Length of hospital stay before and after HAP/VAP (number of days spent in hospital before and after HAP/VAP onset). From the date of enrolment through to the date of hospital discharge, on average of 12 days
See also
  Status Clinical Trial Phase
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Not yet recruiting NCT04057625 - Transthoracic Ultrasound in the Diagnosis and Follow-up of Ventilator Associated Pneumonia N/A
Not yet recruiting NCT03267693 - Gastrointestinal Complications in Association With Oropharyngeal and Respiratory Infections in Mechanical Ventilation N/A
Completed NCT02078999 - Biomarkers in Patients Undergoing Mechanical Ventilation N/A
Completed NCT00726167 - Serum Procalcitonin Study in the Management of Ventilated Patients N/A
Recruiting NCT05124977 - Antimicrobial Stewardship For Ventilator Associated Pneumonia in Intensive Care N/A
Recruiting NCT05331885 - A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2 Phase 3
Completed NCT05517759 - Application of VAP Bundle Among ICU Nurses
Active, not recruiting NCT04488510 - Pathogens Involved in Secondary Infections During Severe Forms of Covid-19 Pneumonia:
Completed NCT03917888 - Clinical Impact of Lung Ultrasound Monitoring for Diagnosis of VAP N/A
Not yet recruiting NCT06066489 - Effect of Educational Program About Preventive Care Bundle for Prevention of Ventilator Associated Pneumonia Among Newborns N/A
Completed NCT02096328 - Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia Phase 2
Terminated NCT00771719 - Open Label Pharmacokinetic in Adult Patients With Ventilator-Associated Pneumonia Phase 1
Recruiting NCT05696093 - Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit Phase 3
Recruiting NCT05354778 - HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study N/A
Not yet recruiting NCT06059040 - Effect of Eliminating Gastric Residual Volume Monitoring on Ventilator Associated Events N/A
Completed NCT04563104 - Lung Ultrasound in Procalcitonin- Guided Antibiotic Discontinuation in Ventilator Associated Pneumonia
Terminated NCT01975350 - Efficacy Study of Colistimethate Sodium Inhalation in Patients With Ventilator-associated Pneumonia
Recruiting NCT06000761 - Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit N/A
Not yet recruiting NCT03294837 - Treatment of Ventilator Associated Pneumonia in Pediatric Intensive Care Unit N/A